Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

Autor: Akdoğan Ö; Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey., Atak Yücel A; Department of Immunology, Faculty of Medicine, Gazi University, Ankara, Turkey., Gök Sargin Z; Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey., Sönmez C; Sexually Transmitted Research Laboratory, National Public Health Institution of Turkey, Ankara, Turkey., Esendağli Yilmaz G; Department of Medical Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey., Özenirler S; Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of clinical and experimental hepatology [J Clin Exp Hepatol] 2019 Jan-Feb; Vol. 9 (1), pp. 29-33. Date of Electronic Publication: 2018 Feb 16.
DOI: 10.1016/j.jceh.2018.02.001
Abstrakt: Background/aims: Progressive hepatic fibrosis is the main predictor of outcome and prognosis in chronic liver diseases. The importance of the coagulation cascade has been defined in liver fibrosis; however, the role of the fibrinolytic pathway has not been clear yet. We aimed to evaluate the association between the plasma levels of soluble urokinase Plasminogen Activator Receptor (uPAR) and the severity of liver fibrosis in chronic hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD).
Methods: 96 chronic hepatitis B, 22 chronic hepatitis C and 11 NAFLD patients together with 47 healthy controls were enrolled in the study. uPAR plasma levels were detected by Enzyme-Linked Immunosorbent Assay (ELISA) method.
Results: The plasma levels of uPAR in patients with chronic hepatitis B and C significantly exceeded those of healthy controls ( P  < 0.001) while mean uPAR levels in patients with NAFLD were not different from healthy controls. Mean uPAR levels in chronic viral hepatitis patients with F1-F3 fibrosis and F4-F6 fibrosis were higher than those of control group ( P  < 0.001). Mean uPAR level in patients with F4-F6 fibrosis was significantly higher than that of patients with F1-F3 fibrosis ( P  < 0.001).
Conclusion: This is the first study that investigated uPAR as a fibrosis marker in NAFLD and chronic hepatitis B patients. It is suggested that plasma levels of uPAR are closely related to the fibrosis stage in chronic hepatitis B and C and that uPAR might be a noninvasive marker of liver fibrosis.
Databáze: MEDLINE
Externí odkaz: